Broadcasting News

Ryu Jun-yeol and Seol Kyung-gu’s ‘The Field Mouse’ Tops Netflix’s Global Non-English Shows Chart

Ranked No. 1 in 45 Countries "Four Hands" Ranks 5th, "This Shitty Love" Ranks 7th

Gim Ga Yeong
2026-09-09 09:13:03
[Edaily Starin Gim Ga Yeong Reporter] The Netflix series “Field Mouse” topped the global Top 10 non-English shows chart in its second week of release.
According to Netflix’s official site, Tudum, from the 31st of last month through the 6th of this month, “Field Mouse” recorded 4.4 million views (views divided by the show’s total runtime) and ranked No. 1 on the global Top 10 non-English TV shows list. Total viewing time was recorded at 41.5 million. The series made the Top 10 in a total of 45 countries, including South Korea, Malaysia, Oman, the Philippines, Argentina, Mexico, Hungary, Egypt, and Nigeria.
“Field Mouse” is a chase thriller that follows novelist “Moon Jae,” who has had his name, face, and entire life stolen by a mysterious entity known as “Field Mouse”; loan shark “No Ja,” who is trying to recover his lost money; and detective “Sun-yong” as they pursue the true identity of Field Mouse.
It was released worldwide as a Netflix series on the 28th of last month and ranked fifth among non-English TV shows in its first week. It reached the top spot in just two weeks.
In addition, the tvN Saturday-Sunday drama “Four Hands,” starring Song Kang and Lee Jun-young, ranked 5th with 2 million views; “Such a Shitty Love,” starring Jung Hae-in and Ha Young, ranked 7th with 1.5 million views; and “Creepy Romance,” starring Park Eun-bin and Yang Se-jong, ranked 10th with 1 million views.
“Field Mouse” is currently streaming on Netflix.

Economy

Corporation

IT·Science

Economy

Xcell Therapeutics Inc. Aims to Raise 8 Billion Won by Year-End… Will It Avoid the Risk of Negative Equity?

#Xcell Therapeutics Inc. is pursuing a third-party private placement worth 7 to 8 billion won to avoid the risk of negative equity by year-end. This comes after the company raised funds through a 9.5 …
2026-11-09 08:02:02

Corporation

GemVax & KAEL Co.,Ltd. Announces Results of 72-Week Clinical Trial for ‘GV1001’ in London… Prepares for Global Phase 3 Clinical Trial Following PSP Trial

GemVax & KAEL Co.,Ltd. announced the results of a 72-week clinical trial for “GV1001,” a candidate drug for progressive supranuclear palsy (PSP), in London, UK. At the event, the company engaged with …
2026-11-09 08:35:02

IT·Science

FLITTO Inc. to Use AI Training with Publishing Data… Building a Legal Trading Market

FLITTO Inc.(300080)is partnering with the Korea Publishers Association to establish a system for processing and supplying published works as high-quality data for artificial intelligence (AI) training…
2026-11-09 08:54:30